[go: up one dir, main page]

EA201170735A1 - Производные бензотиазола в качестве средств против рака - Google Patents

Производные бензотиазола в качестве средств против рака

Info

Publication number
EA201170735A1
EA201170735A1 EA201170735A EA201170735A EA201170735A1 EA 201170735 A1 EA201170735 A1 EA 201170735A1 EA 201170735 A EA201170735 A EA 201170735A EA 201170735 A EA201170735 A EA 201170735A EA 201170735 A1 EA201170735 A1 EA 201170735A1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzthiazole
derivatives
against cancer
means against
symbol
Prior art date
Application number
EA201170735A
Other languages
English (en)
Other versions
EA019447B1 (ru
Inventor
Масанори Оканива
Теруфуми Такаги
Масааки Хиросе
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170735(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201170735A1 publication Critical patent/EA201170735A1/ru
Publication of EA019447B1 publication Critical patent/EA019447B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Предложено конденсированное гетероциклическое производное, демонстрирующее высокую ингибирующую активность в отношении Raf. Предложено соединение формулы (I), где каждый символ является таким, как определено в настоящем описании, или его соль.
EA201170735A 2008-12-02 2009-12-01 Производные бензотиазола в качестве средств против рака EA019447B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008307581 2008-12-02
JP2009125256 2009-05-25
PCT/JP2009/070447 WO2010064722A1 (en) 2008-12-02 2009-12-01 Benzothiazole derivatives as anticancer agents

Publications (2)

Publication Number Publication Date
EA201170735A1 true EA201170735A1 (ru) 2011-12-30
EA019447B1 EA019447B1 (ru) 2014-03-31

Family

ID=42026212

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170735A EA019447B1 (ru) 2008-12-02 2009-12-01 Производные бензотиазола в качестве средств против рака

Country Status (40)

Country Link
US (2) US8143258B2 (ru)
EP (1) EP2358689B9 (ru)
JP (1) JP5640014B2 (ru)
KR (1) KR101639092B1 (ru)
CN (1) CN102300854B (ru)
AR (1) AR074435A1 (ru)
AU (1) AU2009323274B2 (ru)
BR (1) BRPI0922109A2 (ru)
CA (1) CA2745144C (ru)
CL (1) CL2011001299A1 (ru)
CO (1) CO6400140A2 (ru)
CR (1) CR20110366A (ru)
CY (1) CY1117178T1 (ru)
DK (1) DK2358689T5 (ru)
DO (1) DOP2011000165A (ru)
EA (1) EA019447B1 (ru)
EC (1) ECSP11011165A (ru)
ES (1) ES2557304T3 (ru)
GE (1) GEP20146003B (ru)
HR (1) HRP20151370T1 (ru)
HU (1) HUE026491T4 (ru)
IL (1) IL213184A0 (ru)
JO (1) JO3101B1 (ru)
MA (1) MA32911B1 (ru)
ME (1) ME02331B (ru)
MX (1) MX2011005836A (ru)
MY (1) MY150989A (ru)
NZ (1) NZ593759A (ru)
PE (1) PE20110588A1 (ru)
PL (1) PL2358689T3 (ru)
PT (1) PT2358689E (ru)
RS (1) RS54370B9 (ru)
SG (1) SG171426A1 (ru)
SI (1) SI2358689T1 (ru)
SM (1) SMT201500316B (ru)
TN (1) TN2011000280A1 (ru)
TW (1) TWI436987B (ru)
UY (1) UY32281A (ru)
WO (1) WO2010064722A1 (ru)
ZA (1) ZA201104659B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162445B1 (en) * 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8324395B2 (en) * 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8445509B2 (en) * 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
EP2830664A1 (en) * 2012-03-30 2015-02-04 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
AU2014301816B2 (en) 2013-06-28 2017-06-01 Beigene, Ltd. Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103435572B (zh) * 2013-07-16 2015-02-04 浙江医药高等专科学校 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途
CN103382190B (zh) * 2013-07-16 2015-01-14 浙江医药高等专科学校 一类噻唑并环己烷类化合物、其制备方法和用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CN106232583B (zh) 2014-02-20 2020-04-24 康奈尔大学 用于抑制肌成束蛋白的化合物和方法
CA2954764A1 (en) 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Methods and devices for predicting anthracycline treatment efficacy
JP2018502087A (ja) * 2014-12-23 2018-01-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒａｆ阻害剤及びタキサンの組み合わせ
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
CN109053630B (zh) * 2018-08-22 2022-04-01 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途
US20230148448A9 (en) * 2018-11-07 2023-05-11 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020232445A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Modulators of pyrimidine nucleotide biosynthetic pathways
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN112094248B (zh) * 2020-09-17 2023-05-12 中国人民解放军海军军医大学 一种取代苯并噻唑类化合物及其用途
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
JP2024540292A (ja) 2021-11-09 2024-10-31 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CN115724837B (zh) * 2022-10-26 2024-07-23 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399026A (en) * 1941-02-06 1946-04-23 Chem Ind Basel Amides of 2-aminoarylenethiazoles
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
NZ503432A (en) 1997-09-26 2002-11-26 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
ATE460398T1 (de) * 1999-01-13 2010-03-15 Bayer Healthcare Llc Verwendung von omega-carboxyaryl-substituierten diphenylharnstoffen als raf-kinase-inhibitoren
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU771504B2 (en) * 1999-01-22 2004-03-25 Kyowa Hakko Kirin Co., Ltd. Quinoline derivatives and quinazoline derivatives
AU5570600A (en) 1999-07-01 2001-01-22 Ajinomoto Co., Inc. Heterocyclic compounds and medicinal use thereof
CA2389767C (en) 1999-11-05 2010-03-23 Laurent Francois Andre Hennequin Quinazoline derivatives as vegf inhibitors
SK12712002A3 (sk) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
CO5280092A1 (es) 2000-02-15 2003-05-30 Sugen Inc Indolinas susutituidas con pirroles inhibidoras de proteinquinasas
ATE266022T1 (de) 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
PT1303272E (pt) 2000-06-21 2008-04-14 Hoffmann La Roche Derivados de benzotiazole
CN1471523A (zh) 2000-09-21 2004-01-28 ʷ 咪唑类棉子糖激酶抑制剂
CN1308310C (zh) 2000-10-20 2007-04-04 卫材R&D管理有限公司 含氮芳环衍生物
AU2002232439A1 (en) * 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
ATE403653T1 (de) 2001-09-05 2008-08-15 Smithkline Beecham Plc Pyridin-substituierte furanderivate als raf- kinase inhibitoren
EP1432703A1 (en) 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivatives as raf kinase inhibitors
AU2003220970A1 (en) 2002-03-01 2003-09-16 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EP1499311B1 (en) * 2002-03-29 2009-11-04 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as raf kinase inhibitors
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10334663A1 (de) * 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
WO2005037273A1 (en) 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
EP1751124A4 (en) 2004-05-07 2010-04-14 Exelixis Inc RAF MODULATORS AND METHODS OF USE
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20060079098A (ko) 2004-12-31 2006-07-05 주식회사 엘지생명과학 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체
WO2006076376A1 (en) 2005-01-11 2006-07-20 Medicinova, Inc. Topical treatment of solid tumors and ocular neovascularization
CN101106990B (zh) * 2005-01-26 2010-12-08 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
PE20080538A1 (es) 2006-08-04 2008-06-18 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
WO2008084873A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
ATE540676T1 (de) 2007-04-13 2012-01-15 Rikshospitalet Radiumhospitalet Hf Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
AU2008256922B2 (en) 2007-05-23 2011-07-28 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP2008307581A (ja) 2007-06-15 2008-12-25 Sanyo Special Steel Co Ltd 管材の洗浄装置
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028655A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2009125256A (ja) 2007-11-22 2009-06-11 Kandado:Kk 安眠枕
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20090275546A1 (en) * 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
US8497274B2 (en) 2013-07-30
PL2358689T3 (pl) 2016-03-31
CR20110366A (es) 2011-08-29
AU2009323274A1 (en) 2011-07-07
KR20110091039A (ko) 2011-08-10
HK1161236A1 (zh) 2012-08-24
US20120214855A1 (en) 2012-08-23
GEP20146003B (en) 2014-01-10
CN102300854B (zh) 2015-01-07
EP2358689A1 (en) 2011-08-24
EP2358689B9 (en) 2016-08-03
ES2557304T3 (es) 2016-01-25
EA019447B1 (ru) 2014-03-31
AU2009323274B2 (en) 2015-09-17
CL2011001299A1 (es) 2012-01-13
AR074435A1 (es) 2011-01-19
US20100216810A1 (en) 2010-08-26
HUE026491T2 (en) 2016-06-28
US8143258B2 (en) 2012-03-27
RS54370B9 (sr) 2020-01-31
HRP20151370T1 (hr) 2016-01-15
IL213184A0 (en) 2011-07-31
CO6400140A2 (es) 2012-03-15
CN102300854A (zh) 2011-12-28
SI2358689T1 (sl) 2016-01-29
PE20110588A1 (es) 2011-09-08
ECSP11011165A (es) 2011-07-29
JO3101B1 (ar) 2017-09-20
HUE026491T4 (en) 2017-07-28
CA2745144C (en) 2017-10-03
CA2745144A1 (en) 2010-06-10
BRPI0922109A2 (pt) 2020-09-01
NZ593759A (en) 2012-07-27
MA32911B1 (fr) 2011-12-01
CY1117178T1 (el) 2017-04-05
KR101639092B1 (ko) 2016-07-12
JP5640014B2 (ja) 2014-12-10
MX2011005836A (es) 2011-06-17
TWI436987B (zh) 2014-05-11
ZA201104659B (en) 2012-08-29
DK2358689T5 (en) 2016-10-10
ME02331B (me) 2016-04-28
RS54370B1 (en) 2016-04-28
UY32281A (es) 2010-06-30
JP2012510467A (ja) 2012-05-10
SMT201500316B (it) 2016-01-08
SG171426A1 (en) 2011-07-28
TN2011000280A1 (en) 2012-12-17
EP2358689B1 (en) 2015-09-30
TW201024272A (en) 2010-07-01
DOP2011000165A (es) 2011-06-30
DK2358689T3 (en) 2015-12-14
MY150989A (en) 2014-03-31
WO2010064722A1 (en) 2010-06-10
PT2358689E (pt) 2015-12-30

Similar Documents

Publication Publication Date Title
EA201170735A1 (ru) Производные бензотиазола в качестве средств против рака
CY1121792T1 (el) Ετεροκυκλικη ενωση
EA201071032A1 (ru) Гетероциклическое соединение
BRPI1012770B8 (pt) derivados de tiofeno
CR11021A (es) Derivados de quinolina como fungicidas
SMAP201100019A (it) Composti organici.
AU2011232516A8 (en) Chemical compounds
EA201290401A1 (ru) Азотсодержащее гетероциклическое соединение и сельскохозяйственный фунгицид
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
CR20110432A (es) Pirimidinas fusionadas
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
EA201071229A1 (ru) Производные иминопиридина и их применение
MY157497A (en) Pyrazinooxazepine derivatives
EA200971044A1 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
EA201892449A1 (ru) Конденсированные гетероциклические соединения
EP2602254A4 (en) HETEROCYCLIC CONNECTION
MX2013002511A (es) Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
ECSP11011081A (es) 3-aminociclopentancarboxamidas
BR112012012987A2 (pt) derivados de diona espiroheterocíclica utilizados como pesticidas.
BR112012030414A2 (pt) derivados 1,8-diazaespiro[4.5]decano-2,4-diona úteis como pesticidas
EA201201674A1 (ru) Способы разделения замещенных по атому азота производных (s)-5-алкокси-2-аминотетралина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM